$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
PARP抑制剂尼拉帕尼治疗卵巢癌的疗效
2025-10-19 11:44:20
Check Details
奥拉帕尼用于卵巢癌患者术后的维持疗法
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗铂敏感复发性浆液性卵巢癌患者
2025-10-19 11:44:20
Check Details
尼拉帕利延长存在BRCA 突变患者的生存期
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗BRCA突变卵巢癌患者疗效显著
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗卵巢癌优于安慰剂
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗复发性卵巢癌时,效果如何?
2025-10-19 11:44:20
Check Details
卵巢癌患者PARP抑制剂尼拉帕尼
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗存在BRCA突变的卵巢癌患者
2025-10-19 11:44:20
Check Details
铂类耐药的卵巢癌患者可服用索拉非尼进行治疗
2025-10-19 11:44:20
Check Details
尼拉帕尼( Niraparib )治疗复发性卵巢癌
2025-10-19 11:44:20
Check Details
帕唑帕尼治疗上皮性卵巢癌
2025-10-19 11:44:20
Check Details
1
2
...
6846
6847
6848
6849
6850
6851
6852
...
10232
10233
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
2
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
3
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
4
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
5
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
6
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
7
Fezolinetant (Veozah) Dosing and Liver Monitoring Guide
8
Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications
9
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment